作者
Cordula Stillhart, Katarina Vučićević, Patrick Augustijns, Abdul W Basit, Hannah Batchelor, Talia R Flanagan, Ina Gesquiere, Rick Greupink, Daniel Keszthelyi, Mikko Koskinen, Christine M Madla, Christophe Matthys, Goran Miljuš, Miriam G Mooij, Neil Parrott, Anna-Lena Ungell, Saskia N De Wildt, Mine Orlu, Sandra Klein, Anette Müllertz
发表日期
2020/4/30
来源
European Journal of Pharmaceutical Sciences
卷号
147
页码范围
105280
出版商
Elsevier
简介
The release and absorption profile of an oral medication is influenced by the physicochemical properties of the drug and its formulation, as well as by the anatomy and physiology of the gastrointestinal (GI) tract. During drug development the bioavailability of a new drug is typically assessed in early clinical studies in a healthy adult population. However, many disease conditions are associated with an alteration of the anatomy and/or physiology of the GI tract. The same holds true for some subpopulations, such as paediatric or elderly patients, or populations with different ethnicity. The variation in GI tract conditions compared to healthy adults can directly affect the kinetics of drug absorption, and thus, safety and efficacy of an oral medication.
This review provides an overview of GI tract properties in special populations compared to healthy adults and discusses how drug absorption is affected by these conditions …
引用总数
学术搜索中的文章
C Stillhart, K Vučićević, P Augustijns, AW Basit… - European Journal of Pharmaceutical Sciences, 2020